Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$1.58 USD
-0.05 (-3.07%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1.58 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Regulus Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -30.04 | -28.32 | -27.81 | -15.73 | -18.59 |
Depreciation/Amortization & Depletion | 0.07 | -0.06 | 0.46 | 0.47 | 0.93 |
Net Change from Assets/Liabilities | 0.26 | 0.55 | 0.91 | -0.04 | -6.58 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 2.94 | 2.31 | 2.31 | 2.77 | 4.42 |
Net Cash From Operating Activities | -26.77 | -25.53 | -24.13 | -12.54 | -19.82 |
Property & Equipment | -0.61 | -0.36 | -0.25 | 0.00 | 0.10 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | -0.01 | -0.02 |
Investments | 15.10 | -14.76 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | -0.01 | -0.02 |
Net Cash from Investing Activities | 14.49 | -15.12 | -0.25 | -0.01 | 0.07 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 15.12 | 4.49 | 53.82 | 19.13 | 42.17 |
Issuance (Repayment) of Debt | -3.30 | 0.00 | -0.08 | -9.62 | -2.24 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | -0.28 | -0.26 |
Net Cash from Financing Activities | 11.82 | 4.49 | 53.74 | 9.51 | 39.93 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -0.46 | -36.16 | 29.36 | -3.03 | 20.19 |
Cash at Beginning of Period | 24.29 | 60.45 | 31.09 | 34.12 | 13.94 |
Cash at End of Period | 23.83 | 24.29 | 60.45 | 31.09 | 34.12 |
Diluted Net EPS | -1.58 | -1.86 | -3.20 | -4.50 | -10.80 |
Fiscal Year End for Regulus Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -19.51 | -8.47 | -30.04 | -21.98 | -14.15 |
Depreciation/Amortization & Depletion | -0.41 | 0.21 | 0.07 | 0.04 | 0.04 |
Net Change from Assets/Liabilities | -3.36 | -1.50 | 0.26 | -0.59 | -1.13 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 2.89 | 1.02 | 2.94 | 1.88 | 0.87 |
Net Cash From Operating Activities | -20.38 | -8.74 | -26.77 | -20.64 | -14.37 |
Property & Equipment | -0.31 | -0.23 | -0.61 | -0.54 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -78.32 | -78.32 | 15.10 | 10.10 | 15.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -78.63 | -78.54 | 14.49 | 9.56 | 15.00 |
Uses of Funds
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 93.74 | 93.93 | 15.12 | 15.17 | 14.05 |
Issuance (Repayment) of Debt | -1.38 | -0.83 | -3.30 | -2.48 | -1.65 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 92.36 | 93.11 | 11.82 | 12.69 | 12.40 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -6.65 | 5.82 | -0.46 | 1.61 | 13.04 |
Cash at Beginning of Period | 23.83 | 23.83 | 24.29 | 24.29 | 24.29 |
Cash at End of Period | 17.18 | 29.65 | 23.83 | 25.90 | 37.33 |
Diluted Net EPS | -0.17 | -0.29 | -0.39 | -0.40 | -0.37 |